Status message

Not the entire site translated, but only to "Journal"

Cognitive impairment in major depression: an analysis of problems and potential solutions (review)

Akhapkin R.V.
Federal Medical Research Centre for Psychiatry and Narcology named after V.P. Serbsky

Summary: Cognitive impairments are frequently accompanies major depressive disorder. Moreover, they tend to persist during remission, greatly affect the quality of life of patients, including social and professional integration. Despite the large number of attempts to characterize the cellular and cerebral mechanisms underlying cognitive functions, define the nature and causes of cognitive impairment in depressive disorders and develop methods for their correction, the problem is still far from being solved without validation of theoretical conclusions and research diagnostic criteria. This article provides a critical assessment of the existing notions of cognitive impairment, highlights the difficulties encountered by researchers and discusses further opportunities to improve the cognitive functioning of patients with depressive disorders.

References: 
  • 1. Krasnov V.N. i dr. Vzaimosvyazi kognitivnykh i ehmotsional'nykh narushenij pri depressiyakh (obzor literatury) // Doktor.Ru. – 2013. – № 5 (83). – S. 1–6.
  • 2. Marazziti D. et al. Cognitive impairment in major depression // Eur J Pharmacol. – 2010. – No 626 (1). – P. 83–86.
  • 3. Wittchen H.U. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 // Eur Neuropsychopharmacol. – 2011. – No 21 (9). – P. 655–679.
  • 4. Аleksandrovskij YU.А. Pogranichnye psikhicheskie rasstrojstva. – M.: Meditsina, 2000. – 301 s.
  • 5. Rihmer Z., Angst J. Mood disorders: epidemiology // B.J. Sadock, V.A. Sadock (eds.). Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. – 8th ed. – New York: Lippincott Williams & Wilkins, 2005. – P. 1575–1582.
  • 6. McIntyre R.S. et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions // Depress Anxiety. – 2013. – 30. – P. 515–527.
  • 7. Potter G.G. et al. Prefrontal neuropsychological predictors of treatment remission in late-life depression. // Neuropsychopharmacology. – 2004. – No 29 (12). – P. 2266–2271.
  • 8. Ashby W.R. The contribution of information theory to pathological mechanisms in psychiatry // Br J Psychiatry. – 1968. – No 114 (517). – P. 1485–1498.
  • 9. Simonov P.V. EHmotsional'nyj mozg. – M: Nauka, 1981. – 215 c.
  • 10. Alon U. Network motifs: theory and experimental approaches // Nat Rev Genet. – 2007. – No 8 (6). – P. 450–461.
  • 11. Foland-Ross L.C. et al. The neural basis of difficulties disengaging from negative irrelevant material in major depression // Psychol Sci. – 2013. – No 24 (3). – P. 334–344.
  • 12. Gotlib I.H., Joormann J. Cognition and depression: current status and future directions // Annu Rev Clin Psychol. – 2010. – No 6. – P. 285–312.
  • 13. Millan M.J. et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy // Nat Rev Drug Discov. – 2012. – No 11 (2). – P. 141–168.
  • 14. Moylan S. et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications // Mol Psychiatry. – 2013. – No 18 (5). – P. 595–606.
  • 15. Pessoa L. On the relationship between emotion and cognition // Nature Rev Neurosci. – 2008. – No 9. – P. 148–158.
  • 16. Duncan S., Barrett L.F. Affect is a form of cognition: A neurobiological analysis // Cogn Emot. – 2007. – No 21 (6). – P. 1184–1211.
  • 17. Feinstein J.S. et al. The human amygdala and the induction and experience of fear // Curr Biol. – 2011. – No 21 (1). – P. 34–38.
  • 18. Baars B.J., Gage N.M. Cognition B. Consciousness: Introduction to Cognitive Neuroscience. – Burlington, MA: Academic Press/Elsevier, 2010. – 653 p.
  • 19. Kandel E.R. et al. (eds.) Principles of neural science. – 5th ed. – New York, Chicago, San-Francisco: McGraw-Hill Companies, 2012.
  • 20. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application // Pharmacol Ther. – 2006. – No 110. – P. 135–370.
  • 21. Repantis D. et al. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review // Pharmacol Res. – 2010. – No 61 (6). – P. 473–481.
  • 22. Pérez-Edgar K. et al. Variations in the serotonin-transporter gene are associated with attention bias patterns to positive and negative emotion faces // Biol Psychol. – 2010. – No 83 (3). – P. 269–271.
  • 23. Picciotto M.R. et al. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior // Neuron. – 2012. – No 76 (1). – P. 116–129.
  • 24. Mosolov S.N. Sovremennye biologicheskie gipotezy rekurrentnoj depressii // ZHurnal nevrologii i psikhiatrii im. C.C. Korsakova. – 2012. – T. 11, № 11–2. – S. 29–40.
  • 25. Vertogradova O.P., TSelishhev O.V. Depressivnye idei v strukture rekurrentnoj i bipolyarnoj nepsikhoticheskoj depressii i ikh terapevticheskaya dinamika // Rossijskij psikhiatricheskij zhurnal. – 2011. – № 3. – S. 31–37.
  • 26. Cohen R. et al. Impairments of attention and effort among patients with major affective disorders // The Journal of Neuropsychiatry and Clinical Neurosciences. – 2001. – No 13. – P. 385–395.
  • 27. Hammar A. et al. Selective impairment in effortful information processing in major depression // Journal of the International Neuropsychological Society: JINS. – 2003. – No 9. – P. 954–959.
  • 28. Vythilingam M. et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment // Biological Psychiatry. – 2004. – No 56. – P. 101–112.
  • 29. Porter R.J. et al. Neurocognitive impairment in drug-free patients with major depressive disorder // The British Journal of Psychiatry: The Journal of Mental Science. – 2003. – No 182. – P. 214–220.
  • 30. Landro N.I. et al. Neuropsychological function in nonpsychotic unipolar major depression // Neuropsychiatry, Neuropsychology, and Behavioral Neurology. – 2001. – No 14. – P. 233–240.
  • 31. Taylor Tavares J.V. et al. Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression // Biological Psychiatry. – 2007. – No 62. – P. 917–924.
  • 32. Wang P.S. et al. Effects of major depression on moment-in-time work performance // The American Journal of Psychiatry. – 2004. – No 161. – P. 1885–1891.
  • 33. Castaneda A.E. et al. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults // Journal of Affective Disorders. – 2008. – No 106. – P. 1–27.
  • 34. Gohier B. et al. Cognitive inhibition and working memory in unipolar depression // Journal of Affective Disorders. – 2009. – No 116. – P. 100–105.
  • 35. Naismith S.L. et al. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors // Journal of Clinical and Experimental Neuropsychology. – 2003. – No 25. – P. 866–877.
  • 36. Airaksinen E. et al. Cognitive functions in depressive disorders: Evidence from a population-based study. // Psychological Medicine. – 2004. – No 34. – P. 83–91.
  • 37. Reischies F.M., Neu P. Comorbidity of mild cognitive disorder and depression – A neuropsychological analysis // European Archives of Psychiatry and Clinical Neuroscience. – 2000. – No 250. – P. 186–193.
  • 38. Austin M.P. et al. Cognitive deficits in depression: Possible implications for functional neuropathology // The British Journal of Psychiatry: The Journal of Mental Science. – 2001. – No 178. – P. 200–206.
  • 39. Majer M. et al. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders // Psychol Med. – 2004. – No 34 (8). – P. 1453–1463.
  • 40. Paelecke-Habermann Y. et al. Attention and executive functions in remitted major depression patients // J Affect Disord. – 2005. – No 89 (1–3). – P. 125–135.
  • 41. Fava M. et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment // The Journal of Clinical Psychiatry. – 2006. – No 67. – P. 1754–1759.
  • 42. Gorwood P. et al. Neurobiological mechanisms of anhedonia // Dialogues Clin Neurosci. – 2008. – No 10 (3). – P. 291–299.
  • 43. Rock P.L. et al. Cognitive impairment in depression: a systematic review and meta-analysis // Psychol Med. – 2013. – No 29. – P. 1–12.
  • 44. Ashcraft M.H., Radvansky G.A. Cognition. – 5th ed. – Boston: Prentice Hall, 2010. – 592 p.
  • 45. Smulevich А.B. Psikhicheskie rasstrojstva v klinicheskoj praktike. – M.: MEDpress-inform, 2011.
  • 46. Cattell R.B. Abilities: Their Structure, Growth, and Action. – Boston: Houghton Mifflin, 1971.
  • 47. Weisenbach S.L. et al. Depression and Cognitive Impairment in Older Adults // Curr Psychiatry Rep. – 2012. – No 14. – P. 280–288.
  • 48. Fajzulloev А.Z., Аkhapkin R.V. Osobennosti psikhofiziologicheskikh ehffektov antidepressantov // Farmateka. –2012. – № 19. – M.: Bionika, 2012. – S. 62–65.
  • 49. Goldstein B.J., Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics // J Psychopharmacol. – 1998. – No 12 (3), Suppl. B. – P. 55–87.
  • 50. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) // Int Clin Psychopharmacol. – 1994. – No 9 (1). – P. 9–26.
  • 51. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis // Int Clin Psychopharmacol. – 1995. – No 9 (4). – P. 33–40.
  • 52. Аvedisova А.S., Spasova S.А. Vliyanie antidepressantov na intellektual'no-mnesticheskie funktsii kak otrazhenie ikh povedencheskoj toksichnosti // Sotsial'naya i klinicheskaya psikhiatriya. – 2000. – № 2. – S. 30–34.
  • 53. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. – M., 1995.
  • 54. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov // Russkij meditsinskij zhurnal. – 2005. – T. 13, № 12. – S. 852–857.
  • 55. Amado-Boccara I., Danion J.M. Cognitive impact of antidepressants // Encephale. – 1994. – No 20 (1). – P. 215–222.
  • 56. Kruglikov R.I. Nejrokhimicheskie mekhanizmy pamyati i naucheniya. – M.: Nauka, 1981.
  • 57. Krasnov V.N. Sovremennye podkhody k terapii depressij // Russkij meditsinskij zhurnal. – 2002. – № 12. – S. 553–555.
  • 58. Allain H. et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline // Psychopharmacology (Berl). – 1992. – No 106, Suppl. – P. 56–61.
  • 59. Fairweather D.B. et al. Citalopram Compared to Dothiepin and Placebo: Effects on Cognitive Function and Psychomotor Performance // Human Psychopharmacology: Clinical and Experimental. – 1997. – No 12 (2). – P. 119–126.
  • 60. Fairweather D.B. et al. Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers // Pharmacol Biochem Behav. – 1996. – No 53 (2). – P. 265–269.
  • 61. Cassano G.B. et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients // The Journal of Clinical Psychiatry. – 2002. – No 63 (5). – P. 396–402.
  • 62. Herrera-Guzmán I. et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder // Psychiatry Res. – 2008. – No 160 (1). – P. 72–82.
  • 63. Nieoullon A., Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition // Curr Opin Neurol. – 2003. – No 16, Suppl. 2. – P. 3–9.
  • 64. Raddatz R. et al. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases // Curr Top Med Chem. – 2010. – No 10. – P. 153–169.
  • 65. Codony X. et al. 5-HT6 receptors and cognition // Curr Opin Pharmacol. – 2011. – No 11. – P. 94–100.
  • 66. Meyer-Lindenberg A. et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine // Nature Rev Neurosci. – 2011. – No 12. – P. 524–538.
  • 67. Sarter M. et al. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms // Biochem Pharmacol. – 2009. – No 10. – P. 658–667.